



pharmaceuticals ltd.

**Registered & Corporate Office :**

Plot No. 19-111, Road No. 71,  
Opp. Bharatiya Vidya Bhavan Public School,  
Jubilee Hills Hyderabad - 500 096, Telangana, INDIA,  
Tel : +91-40-6628 8888, Fax : +91-40-2355 1401/402  
CIN : L24239AP1987PLC008066  
Email : info@smspharma.com, www.smspharma.com

Date: 13<sup>th</sup> September, 2017

To,  
The Manager,  
Corporate Filings Department,  
BSE Limited,  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai- 400 001

The Manager,  
Listing Compliance Department,  
National Stock Exchange of India Ltd.  
Exchange Plaza, Plot no. C/1, G Block,  
Bandra-Kurla Complex, Bandra (E),  
Mumbai - 400 051.

**Security Code:532815**

**Symbol: SMSPHARMA**

**Subject: Outcome of the Board Meeting held on 13<sup>th</sup> September, 2017.**

Dear Sir/Madam,

**With reference to the** above subject, we would like to inform you that the **Board of Directors** of the Company at their meeting held on today and concluded at 5.15 P.M, inter-alia transacted the following items of agenda:

1. Approved the standalone Un-audited Financial Results for the Quarter ended 30<sup>th</sup> June, 2017 along with Limited Review Report.
2. **Appointed Mr.** Lakshmi Narayana Tammineedi as Chief Financial Officer of the Company w.e.f 13<sup>th</sup> September, 2017.


Accordingly, please find enclosed the following;

1. Standalone Un-audited Financial Results for the Quarter ended 30<sup>th</sup> June, 2017 along with Limited Review Report.
2. Brief profile of Mr. Lakshmi Narayana Tammineedi as Chief Financial Officer of the Company.

Please take the above information on your records.

Yours Faithfully,

For SMS Pharmaceuticals Limited



Thirumalesh Tumma  
Company Secretary



**SMS PHARMACEUTICALS LIMITED**

Regd. Office: Plot No.19-III, Opp. BVBP School, Road No.71, Jubilee Hills, Hyderabad - 500 096  
**Statement of Un-Audited Financial Results for the Quarter Ended 30th June, 2017**

(Rs. In Lakhs)

S.No.	Particulars	STANDALONE	
		Quarter Ended	
		30-06-2017 (Unaudited)	30-06-2016 (Unaudited)
1	Revenue From Operations	13,281.80	9,258.09
2	Other Income	41.85	9.70
3	<b>Total Revenue</b>	<b>13,303.65</b>	<b>9,267.79</b>
4	<b>Expenses</b>		
	(a) Cost of materials consumed	7,876.86	7,312.02
	(b) Purchases of stock-in-trade	-	-
	(c) Changes in inventories of finished goods work-in-progress and stock-in trade	1,539.02	(1,289.39)
	(d) Employee Benefits Expense	715.21	613.97
	(e) Finance costs	351.05	407.60
	(f) Depreciation and amortisation expense	493.56	474.75
	(g) Other expenses	1,299.76	1,100.37
	<b>Total Expenses - (a to g)</b>	<b>12,075.46</b>	<b>8,619.32</b>
5	<b>Profit before Exceptional and Extraordinary Items and Tax (3-4)</b>	<b>1,228.19</b>	<b>648.47</b>
6	Exceptional items	-	-
7	<b>Profit before Extraordinary Items and Tax (5-6)</b>	<b>1,228.19</b>	<b>648.47</b>
8	Extraordinary Items	-	-
9	<b>Profit before Tax (7-8)</b>		
10	Tax Expenses		
	(1) Current Tax (MAT)	265.00	150.00
	(2) Deferred Tax	40.09	73.26
11	<b>Net Profit / (Loss) for the Period (9-10)</b>	<b>923.10</b>	<b>425.21</b>
12	Other Comprehensive Income (OCI):		
	Items that will not be reclassified to profit or Loss:	(15.40)	(12.83)
	Tax on Items that will not be reclassified to profit or Loss:	5.33	4.44
		(10.07)	(8.39)
13	<b>Total comprehensive Income for the period (11+12)</b>	<b>913.03</b>	<b>416.82</b>
14	Earning Per Equity Share	1.09	0.50
	(of Re.1/ each) (not annualised)		
	(a) Basic		
	(b) Diluted		
	Paid-up equity share capital (Face Value of Re.1/- each)	846.52	846.52
	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year		



**Notes:**

- 1 The above standalone Financial Results have been reviewed and recommended by the Audit Committee on 12th September, 2017 and have been approved by the Board of Directors at its meeting held on 13th September, 2017.
- 2 Results for the quarter ended 30th June, 2017 were subjected to 'Limited Review' by the Auditors.
- 3 The Company has adopted Indian Accounting Standards (IND-AS), prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder, with effect from 01st April, 2017, with transition date April 1, 2016. The unaudited Standalone Financial Results has been prepared by the Company in accordance with IND AS notified under the Company's (Indian Accounting Standards) Rules, 2015 as amended by the Companies (Indian Accounting Standards) (Amendment) Rules, 2016. The financial results have been prepared in accordance with recognition and measurement principles laid down in IND AS 34 Interim Financial Reporting.

The Ind AS compliant financial results pertaining to quarter ended 30th June, 2016 has not been subjected to limited review in line with SEBI Circular no. CIR/CFD/FAC/62/2016 dated 05th July, 2016. However, the management has exercised necessary due diligence to ensure that the financial results provide a true and fair view of its affairs.

A reconciliation of financial results as reported under Previous Indian GAAP (referred as "IGAAP") and IND-AS is summarised below:

(Rs.in Lakhs)	
Particulars	Quarter ended 30.06.2016
Net Profit as per previous GAAP (Indian GAAP)	421.41
Ind AS adjustments:	
Actuarial loss on employee defined benefit funds recognised in Other Comprehensive Income	12.83
Others	(9.91)
Deferred taxes on Ind AS adjustments	0.88
Net Profit as per Ind AS	425.21
Other Comprehensive Income, net of Income Tax	(8.39)
Total comprehensive Income for the period	416.82

- 4 The Company is engaged in the manufacturing of Active Pharmaceutical Ingredients and intermediates and the same constitutes a single reportable business segment as per Ind AS108.
- 5 As per Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, the company has opted to publish quarterly unaudited standalone and to publish consolidated results at the year end.
- 6 Figures of previous period have been regrouped / rearranged wherever necessary.

Place: Hyderabad  
Date : 13-09-2017



For SMS Pharmaceuticals Limited

  
Ramesh Babu Potluri  
Chairman and Managing Director

Limited Review Report

To  
The Board of Directors  
SMS PHARMACEUTICALS LIMITED  
Hyderabad.

We have reviewed the accompanying statement of unaudited financial results of SMS PHARMACEUTICALS LIMITED ("the Company"), for the quarter ended 30th June 2017("the statement"), being submitted by the company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No.CIR/CFD/FAC/62/2016 dated 5th July,2016.

This statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

As stated in Notes of financial statement, we have not performed a review of the figures relating to the corresponding quarter ended 30th June,2016 including the reconciliation of net profit for the quarter ended 30th June,2016 between the previous GAAP and the Indian Accounting Standards ("Ind AS")

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by Independent Auditor of Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the aforesaid Indian Accounting standards and other accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No.CIR/CFD/FAC/62/2016 dated 5th July,2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad  
Date: 13-09-2017

For RAMBABU & CO.,  
Chartered Accountants  
Reg. No. 0029768



*[Signature]*  
CVL PRASAD  
Partner  
M. No. 026548

### BRIEF PROFILE OF CFO

Name : Lakshmi Narayana Tammineedi

Father's Name : Gopala Krishna Tammineedi

Date of Birth : 06-07-1972

Address : B-58, Madhuranagar, Hyderabad  
Telangana - 500 038

Experience : Mr. Lakshmi Narayana Tammineedi, is Master of Business Administration in Finance and Graduate in Commerce, he has diversified experience in managing various aspects of finance, Accounting and Administration over the past 20 years of his career. He has expertise knowledge in dealing with Banks, budgeting & planning, cash flow management, evaluating new business opportunities & acquisitions, negotiations. He has held several leadership positions looking after strategic initiatives, financial planning, insurance, taxation, investor relations, business finance, contracting and compliances. He has been a strong proponent of Corporate Governance Practices and works closely with the Board. He played significant role in IPO of the company and Acquisitions, Mergers & demergers during the tenure of the company. He is also actively involved in dealing with Financial Institutions, Banks and other regulatory bodies.